Xvir Therapeutics GmbH

Company

    • Company type:
      • Manufacturer
    • Year founded:
    • not available
    • Employees (at the site):
    • 50
    • Turnover range:
    • 5m - <10m EUR
    • Products/services:
    • XVir® Therapeutics GmbH is a biopharmaceutical company, which provides YB-1 dependent oncolytic adenoviruses for the treatment of cancer and in particular multidrug-resistant cancer.

    • Core competencies:
    • Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Xvir Therapeutics GmbH was founded in 2004 and is focusing on the clinical development of novel cancer therapies for the treatment of various solid tumors, and in particular of drug-resistant or radiation-resistant tumors. Such cancer therapies are based on the use of oncolytic adenoviruses restoring drug sensitivity and radiation-sensitivity, respectively, of the tumors. Experimental evidence for the efficacy of Xvir’s therapeutic approach has been provided in several animal studies. Xvir’s therapeutic approach is covered by proprietary patents and patent applications, respectively.

    • Language skills:
    • English
    • Key Tech / section:
      • Biotechnology: Therapeutic drug development
    • Industries NACE:
      • 72.19: Other research and experimental development on natural sciences and engineering
      • 72.11: Research and experimental development on biotechnology
    • Certification:
    • not available

    • Sales markets - target industries:
    • not available
    • Sales markets - target countries:
    • not available
    • Cooperation offers:
    • not available
    • Contact person:
    • Dr. Per Sonne Holm (Mr.)
      - Management